Tech & Biotech Under The Radar: The Next Wave of ASX Growth Stories (2025–26)

Technology and biotech sectors are poised for massive growth ahead and the following ASX stocks in these sectors are quietly gaining momentum with the potential to deliver huge upside.

Life360, Inc. (ASX: 360) 

has been on a great growth trajectory which it continued in Q3 2025 as revenue grew by 34% from the same period in last year to US$124.5 million.
The company also announced US$120 million acquisition of Nativo which is an advertising technology company and the company added 170,000 new paying users in the quarter.

The company is expanding into new areas like pet tracking, insurance and finance which will extend its growth story in the upcoming years. 
Life360 expects total revenue for the full year between US$474 million and US$485 million instead of the earlier US$462–482 million range.

Megaport Limited (ASX: MP1) 

is riding the AI wave very well as the company has grown its network to 983 data centres and added 115 in FY25 across 26 countries.
The revenue grew by 16% to $227.1 million and the company ended the year with $102.1 million in cash. 

The company recently completed a $200 million fully underwritten placement for the acquisition of Latitude.sh which is a Compute-as-a-Service company.
Product development is a big focus for the company right now and the launch of AI Exchange links more than 30 GPU infrastructure providers.

Megaport is in a good position for continued expansion as AI adoption and global digital infrastructure investment continues to grow.

PYC Therapeutics Limited (ASX: PYC) 

is a clinical-stage biotechnology company focused on developing RNA-based precision medicines for severe genetic diseases where no approved treatments currently exist.
During Q3 2025 the company advanced all four programs and the polycystic kidney disease program moved into Part B of the Single Ascending Dose study.

Its most advanced RP11 program progressed into an Open Label Extension within the Multiple Ascending Dose study as the company prepares for an FDA Type D meeting to finalise the registrational trial design.
PYC ended the quarter with $135 million in cash and expects a further $20 million R&D rebate in Q1 2026.

Mesoblast Limited (ASX: MSB) 

is showing progress primarily because of its lead therapy Ryoncil which is already approved in the United States for children with steroid-refractory acute graft-versus-host disease.
During the September 2025 quarter, revenue acceleration remained strong as Ryoncil net revenue increased 69% to US$19.1 million from US$12.9 million in the prior quarter.

A major milestone this quarter was the activation of a permanent Healthcare Common Procedure Coding System which standardises insurance billing and improves adoption.
Mesoblast ended the quarter with US$144.7 million in cash and the business is expanding with a growing revenue base and meaningful catalysts ahead.

(Source: Company Reports)